Zacks: Brokerages Anticipate Uniqure NV (QURE) Will Post Earnings of -$0.63 Per Share

Brokerages expect that Uniqure NV (NASDAQ:QURE) will announce ($0.63) earnings per share (EPS) for the current quarter, Zacks reports. Three analysts have made estimates for Uniqure’s earnings, with the lowest EPS estimate coming in at ($0.70) and the highest estimate coming in at ($0.55). Uniqure posted earnings per share of ($0.40) in the same quarter last year, which indicates a negative year over year growth rate of 57.5%. The firm is expected to report its next earnings results on Wednesday, November 7th.

On average, analysts expect that Uniqure will report full year earnings of ($2.44) per share for the current year, with EPS estimates ranging from ($3.34) to ($1.96). For the next fiscal year, analysts forecast that the firm will report earnings of ($2.84) per share, with EPS estimates ranging from ($3.76) to ($2.40). Zacks Investment Research’s earnings per share averages are an average based on a survey of sell-side research firms that cover Uniqure.

Uniqure (NASDAQ:QURE) last issued its earnings results on Wednesday, August 8th. The biotechnology company reported ($0.57) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.61) by $0.04. The business had revenue of $3.05 million for the quarter, compared to analyst estimates of $3.37 million. Uniqure had a negative net margin of 677.98% and a negative return on equity of 72.12%.

A number of brokerages have recently issued reports on QURE. Cantor Fitzgerald set a $58.00 target price on shares of Uniqure and gave the company a “buy” rating in a research note on Wednesday, October 3rd. BidaskClub lowered shares of Uniqure from a “strong-buy” rating to a “buy” rating in a research note on Friday, September 28th. HC Wainwright increased their price objective on shares of Uniqure from $42.00 to $48.00 and gave the stock a “buy” rating in a research note on Monday, September 24th. Cowen reiterated a “buy” rating on shares of Uniqure in a research note on Monday, August 13th. Finally, Janney Montgomery Scott reiterated a “buy” rating on shares of Uniqure in a research note on Wednesday, August 8th. Two analysts have rated the stock with a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus target price of $45.56.

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Quantbot Technologies LP raised its stake in Uniqure by 3,972.6% during the first quarter. Quantbot Technologies LP now owns 5,498 shares of the biotechnology company’s stock worth $129,000 after acquiring an additional 5,363 shares during the period. Ladenburg Thalmann Financial Services Inc. raised its stake in Uniqure by 276.5% during the first quarter. Ladenburg Thalmann Financial Services Inc. now owns 6,400 shares of the biotechnology company’s stock worth $150,000 after acquiring an additional 4,700 shares during the period. Financial Gravity Wealth Inc. acquired a new stake in Uniqure during the first quarter worth about $177,000. Gagnon Securities LLC bought a new position in Uniqure in the 2nd quarter worth about $209,000. Finally, Jane Street Group LLC bought a new position in Uniqure in the 1st quarter worth about $224,000. Hedge funds and other institutional investors own 59.32% of the company’s stock.

Shares of Uniqure stock traded down $0.75 during trading on Monday, reaching $29.14. The company had a trading volume of 360,000 shares, compared to its average volume of 348,158. The firm has a market cap of $1.36 billion, a PE ratio of -9.84 and a beta of 0.27. The company has a debt-to-equity ratio of 0.06, a quick ratio of 8.36 and a current ratio of 8.36. Uniqure has a fifty-two week low of $9.47 and a fifty-two week high of $43.23.

Uniqure Company Profile

uniQure N.V., a gene therapy company, engages in the discovery, development, and commercialization of gene therapies in the Netherlands. The company develops AMT-060, which is in Phase I/II clinical trial to treat hemophilia B; AMT-061, a gene therapy that is in Phase III clinical trial for the treatment of hemophilia; and AMT-126, a gene therapy for the treatment of congestive heart failure and AMT-130 to treat huntington's disease.

See Also: Stock Symbol

Get a free copy of the Zacks research report on Uniqure (QURE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Uniqure (NASDAQ:QURE)

Receive News & Ratings for Uniqure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Uniqure and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply